Sepsis and Myocarditis

ConditionSepsis-related Myocarditis

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorJimma University

About this trial

This prospective cohort study aims to investigate the cardiac manifestations of sepsis and their influence on disease outcomes among adult patients at Jimma University Medical Center, Ethiopia, from May 2025 to May 2026. The research will include adults aged 18 and older with sepsis, categorizing them based on the presence or absence of cardiac involvement, which will be assessed through clinical symptoms, biomarkers, ECG, and echocardiographic findings. The study will evaluate the persistence of cardiac abnormalities, functional capacity, and survival over one year, utilizing structured data collection and advanced statistical methods, including survival analysis and regression techniques, to identify predictors of adverse outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

All adult patients aged 18 years and above diagnosed with sepsis admitted to Jimma University Medical Center during the study periods that are willing to participate and continue follow-up of their disease condition for at least one year.

Disqualifiers

Patients with any kind of pre-existing established cardiac disease prior to their sepsis diagnosis and those who are not willing to participate or not willing to have follow-up of their disease condition for at least one year.

Trial population

The study population will include all adult septic patients admitted to JUMC during the study period.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Standard treatment for sepsis of any focus
Other intervention
This group of patients will be treated for the sepsis of any focus as per standard.
Treatment for the sepsis with standard management of cardiac failure
Other intervention
This group of patients will be treated for the sepsis and management of cardiac failure with additional supportive care cocktails based on the specific indication.

Treatment groups

226 Participants

are divided into 2 treatment groups

Group A: Group A1 intervention

Group B: Group B1 intervention

Trial outcomes

Primary outcomes

Composite outcomes of survival status and persistence or resolution of cardiac abnormalities.

Outcomes will be assessed at the first, third, and sixth months post-discharge, with evaluations focusing on the following parameters: * Persistence or resolution of cardiac abnormalities * Survival status (alive or deceased) * Functional capacity and quality of life using standardized tools (KCCS).

Time frame

at first, third and sixth- months post discharge

Secondary outcomes

Composite outcomes of persistence or resolution of cardiac abnormalities, Survival status (alive or deceased) and functional capacity and quality of life using standardized tools (KCCS).

Outcomes will be assessed at six months post-discharge, with evaluations focusing on the following parameters: * Persistence or resolution of cardiac abnormalities * Survival status (alive or deceased) * Functional capacity and quality of life using standardized tools (KCCS).

Time frame

at sixth- months post discharge

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Jimma University

Lead sponsor

Ethiopian Society of Cardiac Professionals

Collaborator

Source ClinicalTrials.gov

Apply now